Why the study?
Does exogenous hydrogen sulfide protect against doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells?
Population
H9c2 cardiac cells exposed to 5μM doxorubicin for 24 h to establish a model of cardiotoxicity
Comparison
Pretreatment with NaHS for 30 min before… vs Doxorubicin exposure without NaHS pretreatment
Design
Preclinical
Follow-up
24 hours
Authors
Loading...
May support hydrogen sulfide donors against doxorubicin cardiotoxicity; hypothesis-generating and leaves open clinical translation.
Does exogenous hydrogen sulfide protect against doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells?
Exogenous hydrogen sulfide protects H9c2 cardiac cells from doxorubicin-induced cardiotoxicity by inhibiting the p38 MAPK/NF-κB inflammatory pathway.
Guo et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: